TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that updated data for ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been selected for presentation at the upcoming third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018, to be held February 1 - 3, 2018, in San Diego, California.
Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, "We look forward to presenting updated data from our Phase 2 study of ublituximab in relapsing multiple sclerosis at the ACTRIMS conference in February. We are highly encouraged by the Phase 2 data we presented at the ECTRIMS-ACTRIMS meeting last year and look forward to seeing additional data on the fully enrolled Phase 2 trial.” Mr. Weiss continued, “In addition to providing updated data this year from our Phase 2 program, our Phase 3 MS trial is well underway and we are targeting complete enrollment in the first quarter of 2019.”
The presentation details are as follows:
- Title: 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
- Poster Presentation Number: P028
- Session: Poster Session 1/ Opening Reception
- Date and Time: Thursday, February 1, 2018 6:00 PM – 8:00 PM PT
A copy of the above referenced abstract can be viewed online through the ACTRIMS meeting website at www.actrims.org. Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
Statements included in this press release, particularly those with respect to anticipating the benefit of the early data seen in the Phase 2 MS trial, anticipating our ability to provide a cost effective treatment or our ability to provide a more convenient treatment option, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete the MS Phase 2 trial; the risk that early clinical results that supported our decision to move forward will not be reproduced in additional patients in expansion cohorts or in the MS Phase 3 program; the risk that the clinical results from the MS Phase 3 program, will be not positive and/or will not support regulatory approval of ublituximab for MS; our ability to successfully and cost-effectively complete the MS Phase 3 program; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Vice President, Investor Relations
TG Therapeutics, Inc.
News Provided by GlobeNewswire
© 2017 GlobeNewswire, Inc. All Rights Reserved